Source:http://linkedlifedata.com/resource/pubmed/id/15819373
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2005-4-11
|
pubmed:abstractText |
Besides major progress in the pharmacologic treatment of severe chronic heart failure, cardiac resynchronization therapy (CRT) has developped over the last ten years. We report the follow-up of the 36 first patients with a CRT device implanted from July 2000 to November 2002 at the CHR de la Citadelle Hospital in Liege. After a mean follow up of 6 months, no death was observed. The functional benefit of resynchronization is validated by a significant improvement in the NYHA class, an increase in the walking distance measured by the six minute walk test from 268 +/- 103 to 342 +/- 106 meters (p < 0.004) and by a not significant rise in the VO2 max (from 11.1 +/- 2.8 to 14 +/- 10 ml/kg/min; P=0.1). The quality of life, assessed by the Minnesota-Living-In-CHF score, improves from 49 +/- 20 to 35 +/- 22 after the six month follow-up (P=0.02) The echocardiogram also shows a better left ventricular ejection fraction at six months, from 24 +/- 7% to 31 +/- 7% (P<0.05). Based on a better NYHA functional class, responders (n=24; 71%) and non responders (n=10; 29%) were compared; a correlation between the functional class change and the improvement of the ejection fraction was documented, but not with the reduction in QRS width. Our registry, with the potential pitfalls of a monocentric prospective study, confirms the feasability, safety and efficacy of CRT in severe chrbnic heart failure uncompletely corrected pharmocalogically. It remains however approximately 30% of non responding patients, in whom the current clinical studies should help identify the right criteria to predict and discriminate responders.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0370-629X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
60
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
101-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15819373-Activities of Daily Living,
pubmed-meshheading:15819373-Aged,
pubmed-meshheading:15819373-Female,
pubmed-meshheading:15819373-Follow-Up Studies,
pubmed-meshheading:15819373-Heart Failure,
pubmed-meshheading:15819373-Humans,
pubmed-meshheading:15819373-Male,
pubmed-meshheading:15819373-Middle Aged,
pubmed-meshheading:15819373-Pacemaker, Artificial,
pubmed-meshheading:15819373-Prognosis,
pubmed-meshheading:15819373-Quality of Life,
pubmed-meshheading:15819373-Treatment Outcome,
pubmed-meshheading:15819373-Ventricular Function, Left
|
pubmed:year |
2005
|
pubmed:articleTitle |
[Clinical value of cardiac resynchronization therapy in patients with congestive heart failure].
|
pubmed:affiliation |
CHR de la Citadelle, Liège.
|
pubmed:publicationType |
Journal Article,
English Abstract
|